Charles River Laboratories International, Inc.
CRL
$197.06
$3.211.66%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.92% | -1.21% | -2.16% | -1.92% | -3.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.92% | -1.21% | -2.16% | -1.92% | -3.67% |
| Cost of Revenue | 0.60% | -0.13% | 0.24% | 1.19% | -1.40% |
| Gross Profit | -3.67% | -3.15% | -6.42% | -7.31% | -7.54% |
| SG&A Expenses | 0.76% | 4.57% | -2.63% | -2.05% | -3.59% |
| Depreciation & Amortization | 2.82% | 5.37% | 3.25% | -6.96% | -13.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.71% | 1.03% | -0.26% | 0.19% | -2.32% |
| Operating Income | -10.36% | -13.73% | -13.03% | -13.53% | -10.82% |
| Income Before Tax | -104.28% | -103.36% | -94.52% | -83.98% | -16.01% |
| Income Tax Expenses | -36.63% | -50.57% | -45.71% | -32.79% | -33.84% |
| Earnings from Continuing Operations | -118.60% | -114.56% | -105.17% | -94.74% | -10.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 36.83% | 48.55% | 69.36% | 46.26% | 24.51% |
| Net Income | -119.42% | -115.18% | -105.69% | -95.32% | -10.77% |
| EBIT | -10.36% | -13.73% | -13.03% | -13.53% | -10.82% |
| EBITDA | -5.90% | 0.55% | -5.39% | -5.03% | -4.43% |
| EPS Basic | -119.22% | -115.64% | -107.41% | -98.13% | -13.56% |
| Normalized Basic EPS | -20.61% | -19.07% | -19.10% | -16.48% | -4.73% |
| EPS Diluted | -119.49% | -115.90% | -107.62% | -98.35% | -13.46% |
| Normalized Diluted EPS | -20.44% | -18.83% | -18.95% | -16.39% | -4.62% |
| Average Basic Shares Outstanding | -2.68% | -1.57% | -0.24% | 0.30% | 0.58% |
| Average Diluted Shares Outstanding | -2.95% | -1.91% | -0.51% | 0.10% | 0.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |